Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

NCT01035437 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no accrual

Conditions

Esophageal Neoplasm

Interventions

DRUG: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)

Sponsor

Roswell Park Cancer Institute